Author details

Full Name

Mark J Mulligan

Affiliation

ORCID

Career Start Year

1988

Papers

204

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38019956	Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-GuÃ©rin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.	J Infect Dis	2024
36725433	Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVÎ¿G-ZEBOV-GP).	Vaccine	2023
36415470	Inflammation durably imprints memory CD4+ T cells.	bioRxiv	2023
37983984	Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes.		2023
37790500	Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum.		2023
37705976	Identification of immunodominant T cell epitopes induced by natural Zika virus infection.	Front Immunol	2023
36911714	Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies.	Front Immunol	2023
37205592	Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial.	Res Sq	2023
37391605	Vaccine Equity: Lessons Learned Exploring Facilitators and Barriers to COVID-19 Vaccination in Urban Black Communities.		2023
37451878	COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.	Vaccine	2023
37389439	Optimized quantification of intra-host viral diversity in SARS-CoV-2 and influenza virus sequence data.		2023
36747786	Multimodal characterization of antigen-specific CD8 <sup>+</sup> T cells across SARS-CoV-2 vaccination and infection.	bioRxiv	2023
34874183	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.	Science Translational Medicine	2022
36173983	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.	PLoS One	2022
35898343	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.	medRxiv	2022
36165097	Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.	Ann Clin Transl Neurol	2022
35640110	Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis.	Rheumatology	2022
36273986	An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT) cells and antibody responses.	Vaccine	2022
35798000	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.	Cell Rep Med	2022
35734087	COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004).		2022
35403000	Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease.	Lancet Rheumatol	2022
35350781	Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies.	Frontiers in Immunology	2022
35465948	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.	eBioMedicine	2022
36560562	Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines.	Vaccines (Basel)	2022
34347939	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.	Arthritis and Rheumatology	2022
34982967	High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals.	Cell Reports	2022
35289960	Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.	Ann Neurol	2022
35107835	Immunogenicity after heterologous third dose COVID-19 vaccination in a heart transplant recipient.	Clinical Transplantation	2022
35081293	Homologous and Heterologous Covid-19 Booster Vaccinations.	N Engl J Med	2022
35137154	Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum.	J Infect Dis	2022
34587382	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.	N Engl J Med	2021
34081073	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.	JAMA	2021
33485646	Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65Â years and older.	Vaccine	2021
33859192	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.	Nat Commun	2021
33692390	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.	Sci Rep	2021
34013020	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic.	Acad Pathol	2021
34060334	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.	mBio	2021
33791698	B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.		2021
33469216	Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.	Nature	2021
34215697	Matrix lumican endocytosed by immune cells controls receptor ligand trafficking to promote TLR4 and restrict TLR9 in sepsis.	Proceedings of the National Academy of Sciences of the United States of America	2021
33999317	Knowledge and Attitudes Toward Covid-19 and Vaccines Among a New York Haredi-Orthodox Jewish Community.	J Community Health	2021
34262052	Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.	npj Vaccines	2021
33990619	Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.	Nat Commun	2021
33564768	Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.		2021
34035003	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.	Annals of the Rheumatic Diseases	2021
33505681	Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.	Clin Transl Immunology	2021
33820835	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.	Sci Transl Med	2021
34312623	Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants.		2021
34311587	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.	mBio	2021
33075363	Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay.	Journal of Immunological Methods	2021